 Esperion Therapeutics reported its Q3 earnings with a beat on EPS and a slight miss on revenue. The company was able to report significant revenue growth and encouraging commercial trends. The highly anticipated CLEAR Outcomes data is expected to be announced in January. I anticipate increased volatility before and after the data readout. 